Advanced drug delivery to the lymphatic system: Lipid-based nanoformulations

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 2733-2744

  Khan, Arshad Ali ^a   Mudassir, Jahanzeb ^a   Mohtar, Noratiqah ^a   Darwis, Yusrida ^a  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

Author keywords

Blood circulation; Lymphatic system; Nanostructured lipid carriers; Solid lipid nanoparticles

Indexed keywords

CARVEDILOL; DRUG CARRIER; EMULSIFYING AGENT; ETOPOSIDE; IDARUBICIN; METHOTREXATE; NANOSTRUCTURED LIPID CARRIER; PACLITAXEL; PENCLOMEDINE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; VINPOCETINE;

AREA UNDER THE CURVE; CONCENTRATION (PARAMETERS); DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG TRANSPORT; DRUG UPTAKE; HYDROPHOBICITY; LIPOSOMAL DELIVERY; LUNG METASTASIS; LYMPHATIC SYSTEM; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NONHUMAN; PARTICLE SIZE; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; REVIEW; SURFACE CHARGE; TIME TO MAXIMUM PLASMA CONCENTRATION;

BLOOD CIRCULATION; LYMPHATIC SYSTEM; NANOSTRUCTURED LIPID CARRIERS; SOLID LIPID NANOPARTICLES;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; LYMPHATIC SYSTEM; NANOMEDICINE; NANOSTRUCTURES;

EID: 84880774809     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S41521     Document Type: Review

References (127)

1. Miteva DO, Rutkowski JM, Dixon JB, Kilarski W, Shields JD, Swartz MA. Transmural flow modulates cell and fluid transport functions of lymphatic endothelium. Circ Res. 2010;106:920-931.
2. Iqbal J, Hussain MM. Intestinal lipid absorption. Am J Physiol Endocrinol Metab. 2009;296:E1183-E1194.
3. O'Driscol CM. Anatomy and physiology of the lymphatics. In: Charman WN, Stella VJ, editors. Lymphatic Transport of Drugs. Boca Raton, FL: CRC Press Inc; 1992.
4. McCarter MD, Clarke JH, Harken AH. Lymphangiogenesis is pivotal to the trials of a successful cancer metastasis. Surgery. 2004;135: 121-124.
5. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004;4:448-456.
6. Sleeman J P. The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res. 2000;157:55-81.
7. Sleeman J P. The relationship between tumors and the lymphatics: what more is there to know. Lymphology. 2006;39:62-68.
8. Muranishi S, Fujita T, Murakami M, Yamamoto A. Potential for lymphatic targeting of peptides. J Control Release. 1997;46:157-164.
9. Porter CJH, Charman WN. Uptake of drugs into the intestinal lymphatics after oral administration. Adv Drug Deliv Rev. 1997;25:71-89.
10. Yoshikawa H, Muranishi S, Kato C, Sezaki H. Bifunctional delivery system for selective transfer of bleomycin into lymphatics via enteral route. Int J Pharm. 1981;8:291-302.
11. Eldridge JH, Hammond CJ, Meulbroeck JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissue. I. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release. 1990;11:205-214.
12. Hawley AE, Davis SS, Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adv Drug Deliv Rev. 1995;17:129-148.
13. Beier R, Gebert A. Kinetics of particle uptake in the domes of Peyer's patches. Am J Physiol. 1998;275(1 Pt 1):G130-G137.
14. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol. 2008;6: 349-362.
15. Myers RA, Stella VJ. Factors affecting the lymphatic transport of penclomedine (NSC-338720), a lipophilic cytotoxic drug: comparison to DDT and hexachlorobenzene. Int J Pharm. 1992;80: 51-62.
16. Haus DJ, Fogal SE, Ficorilli J V, et al. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci. 1998;87:164-169.
17. Wu H, Zhou A, Lu C, Wang L. Examination of lymphatic transport of puerarin in unconscious lymph duct-cannulated rats after administration in microemulsion drug delivery systems. Eur J Pharm Sci. 2011;42: 348-353.
18. Thakkar H, Nangesh J, Parmar M, Patel D. Formulation and characterization of lipid-based drug delivery system of raloxifene-microemulsion and self-microemulsifying drug delivery system. J Pharm Bioallied Sci. 2011;3:442-448.
19. Takada K, Yoshimura H, Shibata N, et al. Effect of administration route on the selective lymphatic delivery of cyclosporin A by lipid surfactant mixed micelles. J Pharmacobiodyn. 1986;9:156-160.
20. Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm. 2001;212:233-246.
21. Holm R, Porter CJ, Edwards GA, Müllertz A, Kristensen HG, Charman WN. Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides. Eur J Pharm Sci. 2003;20:91-97.
22. Yao J, Lu Y, Zhou J P. Preparation of nobiletin in self- microemulsifying systems and its intestinal permeability in rats. J Pharm Pharm Sci. 2008;11:22-29.
23. Dixit AR, Rajput SJ, Patel SG. Preparation and bioavailability assessment of SMEDDS containing valsartan. AAPS PharmSciTech. 2010;11:314-321.
24. Chen Y, Li G, Wu X, et al. Self-microemulsifying drug delivery system (SMEDDS) of vinpocetine: formulation development and in vivo assessment. Biol Pharm Bull. 2008;31:118-125.
25. Li X, Yuan Q, Huang Y, Zhou Y, Liu Y. Development of silymarin self-microemulsifying drug delivery system with enhanced oral bioavailability. AAPS PharmSciTech. 2010;11:672-678.
26. Sun M, Zhai X, Xue K, et al. Intestinal absorption and intestinal lymphatic transport of sirolimus from self-microemulsifying drug delivery systems assessed using the single-pass intestinal perfusion (SPIP) technique and a chylomicron flow blocking approach: linear correlation with oral bioavailabilities in rats. Eur J Pharm Sci. 2011;43:132-140.
27. Singh B, Khurana L, Bandyopadhyay S, Kapil R, Katare OO. Development of optimized self-nano-emulsifying drug delivery s ystems (SNEDDS) of carvedilol with enhanced bioavailability potential. Drug Deliv. 2011;18:599-612.
28. Beg S, Swain S, Singh H P, Patra CN, Rao MB. Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers. AAPS PharmSciTech. 2012;13:1416-1427.
29. Holm R, Tønsberg H, Jørgensen EB, Abedinpour P, Farsad S, Müllertz A. Infuence of bile on the absorption of halofantrine from lipid-based formulations. Eur J Pharm Biopharm. 2012;81:281-287.
30. Moghimi SM, Moghimi M. Enhanced lymph node retention of subcutaneously injected IgG1-PEG2000-liposomes through pentameric IgM antibody-mediated vesicular aggregation. Biochim Biophys Acta. 2008;1778:51-55.
31. Ling R, Li Y, Ya O Q, et al. Lymphatic chemotherapy induces apoptosis in lymph node metastases in a rabbit breast carcinoma model. J Drug Target. 2005;13:137-142.
32. Frenkel V, Etherington A, Greene M, et al. Delivery of liposomal doxorubicin (Doxil) in a breast cancer tumor model: investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure. Acad Radiol. 2006;13:469-479.
33. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (Caelyx/Doxil) versus conventional doxorubicin for frst-line treatment of metastatic breast cancer. Ann Oncol. 2004;15: 440-449.
34. Ling SS, Magosso E, Khan NA, Yuen KH, Barker SA. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev Ind Pharm. 2006;32:335-345.
35. Lawson KA, Anderson K, Snyder RM, et al. Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis. Cancer Chemother Pharmacol. 2004;54:421-431.
36. Latimer P, Menchaca M, Snyder RM, et al. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases. Exp Biol Med (Maywood). 2009;234:1244-1252.
37. Kojima N, Biao L, Nakayama T, Ishii M, Ikehara Y, Tsujimura K. Oligomannosecoated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity. J Control Release. 2008;129:26-32.
38. Harivardhan RL, Sharma RK, Chuttani K, Mishra AK, Murthy RS. Infuence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J Control Release. 2005;105:185-198.
39. Paliwal R, Rai S, Vaidya B, et al. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine. 2009;5:184-191.
40. Zara G P, Bargoni A, Cavalli R, Fundarò A, Vighetto D, Gasco MR. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci. 2002;91:1324-1333.
41. Cavalli R, Zara G P, Caputo O, Bargoni A, Fundarò A, Gasco MR. Transmucosal transport of tobramycin incorporated in SLN after duodenal administration to rats. Part I - a pharmacokinetic study. Pharmacol Res. 2000;42:541-545.
42. Cavalli R, Bargoni A, Podio V, Muntoni E, Zara G P, Gasco MR. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci. 2003;92:1085-1094.
43. Chalikwar SS, Belgamwar VS, Talele VR, Surana SJ, Patil MU. Formulation and evaluation of nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. Colloids Surf B Biointerfaces. 2012;97:109-116.
44. Muchow M, Maincent P, Müller RH, Keck CM. Production and characterization of testosterone undecanoate-loaded NLC for oral bioavail-ability enhancement. Drug Dev Ind Pharm. 2011;37:8-14.
45. Zhuang CY, Li N, Wang M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm. 2010;394:179-185.
46. Zhou L, Chen Y, Zhang Z, He J, Du M, Wu Q. Preparation of tripter-ine nanostructured lipid carriers and their absorption in rat intestine. Pharmazie. 2012;67:304-310.
47. Takakura Y, Matsumoto S, Hashida M, Sezaki H. Enhanced lymphatic delivery of mitomycin C conjugated with dextran. Cancer Res. 1984;44: 2505-2510.
48. Jeong YI, Kim ST, Jin SG, et al. Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J Pharm Sci. 2008;97:1268-1276.
49. Cai S, Xie Y, Bagby TR, Cohen MS, Forrest ML. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J Surg Res. 2008;147:247-252.
50. Maincent P, Thouvenot P, Amicabile C, et al. Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats. Pharm Res. 1992;9:1534-1539.
51. Liggins RT, D'Amours S, Demetrick JS, Machan LS, Burt HM. Paclitaxel loaded poly(L-lactic acid) microspheres for the prevention of intraperitoneal carcinomatosis after a surgical repair and tumor cell spill. Biomaterials. 2000;21:1959-1969.
52. Lu H, Li B, Kang Y, et al. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting. Cancer Chemother Pharmacol. 2007;59:175-181.
53. Liu J, Wong HL, Moselhy J, Bowen B, Wu XY, Johnston MR. Targeting colloidal particulates to thoracic lymph nodes. Lung Cancer. 2006;51:377-386.
54. Liu J, Meisner D, Kwong E, Wu XY, Johnston MR. A novel trans-lymphatic drug delivery system: Implantable gelatin sponge impregnated with PLGA-paclitaxel microspheres. Biomaterials. 2007;28: 3236-3244.
55. McAllaster JD, Cohen MS. Role of the lymphatics in cancer metastasis and chemotherapy applications. Adv Drug Deliv Rev. 2011;63: 867-875.
56. Nune SK, Gunda P, Majeti BK, Thallapally PK, Forrest ML. Advances in lymphatic imaging and drug delivery. Adv Drug Deliv Rev. 2011;63: 876-885.
57. Tran Cao HS, McElroy M, Kaushal S, Hoffman RM, Bouvet M. Imaging of the interaction of cancer cells and the lymphatic system. Adv Drug Deliv Rev. 2011;63:886-889.
58. Moghimi SM, Bonnemain B. Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: applications in lymphos-cintigraphy and indirect lymphography. Adv Drug Deliv Rev. 1999;37: 295-312.
59. Cohen MS, Forrest ML. Lymphatic drug delivery: therapy, imaging and nanotechnology. Preface. Adv Drug Deliv Rev. 2011;63:865-866.
60. Müller RH. Lipid nanoparticles: recent advances. Adv Drug Deliv Rev. 2007;59:375-376.
61. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242: 121-128.
62. Müller RH, Gohla S, Dingler A, Schneppe T. Large-scale production of solid-lipid nanoparticles (SLN) and nanosuspension. In: Wise DL, editor. Handbook of Pharmaceutical Controlled Release Technology. Basel, Switzerland: Marcel Dekker; 2000.
63. Uner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefts as colloidal drug carrier systems. Pharmazie. 2006;61:375-386.
64. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161-177.
65. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for par-enteral drug delivery. Adv Drug Deliv Rev. 2004;56:1257-1272.
66. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47: 165-196.
67. Yuan H, Chen J, Du YZ, Hu FQ, Zeng S, Zhao HL. Studies on oral absorption of stearic acid SLN by a novel fuorometric method. Colloids Surf B Biointerfaces. 2007;58:157-164.
68. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev. 2007;59:491-504.
69. Cai S, Yang Q, Bagby TR, Forrest ML. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev. 2011;63:901-908.
70. Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994;271: 58-65.
71. Videira MA, Botelho MF, Santos AC, Gouveia LF, de Lima JJ, Almeida AJ. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drtablesug Target. 2002;10:607-613.
72. Videira M, Almeida AJ, Fabra A. Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomedicine. 2012;8:1208-1215.
73. Bargoni A, Cavalli R, Caputo O, Fundaro A, Gasco MR, Zara G P. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res. 1998;15:745-750.
74. Haque AK. Pathology of carcinoma of lung: An update on current concepts. J Thorac Imaging. 1991;7:9-20
75. Chen XQ, Stroun M, Magnenat JL. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med. 1996;2: 1033-1035
76. Clark R., Ihde DC., Small-cell lung cancer: Treatment progress and prospects. Oncology. 1998;12:647-658.
77. Zangemeister-Wittke U, Stahel RA. Novel approaches to the treatment of small-cell lung cancer. Cell Mol Life Sci. 1999;55:1585-1598.
78. Langenback EG, Bergofsky EH, Halpern JG, Foster WM. Supramicron-sized particle clearance from alveoli: route and kinetics. J Appl Physiol. 1990;69:1302-1308.
79. McIntire GL, Bacon ER, Toner JL, et al. Pulmonary delivery of nanoparticles of insoluble, iodinated CT X-ray contrast agents to lung draining lymph nodes in dogs. J Pharm Sci. 1998;87:1466-1470.
80. Choi SH, Jin SE, Lee MK, et al. Novel cationic solid lipid nanopar-ticles enhanced p53 gene transfer to lung cancer cells. Eur J Pharm Biopharm. 2008;68:545-554.
81. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:131-155.
82. Saupe A, Wissing SA, Lenk A, Schmidt C, Müller RH. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) - structural investigations on two different carrier systems. Biomed Mater Eng. 2005;15:393-402.
83. Jenning V, Thunemann A F, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm. 2000;199:167-177.
84. Oussoren C, Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev. 2001;50:143-156.
85. Walker JE Jr, Odden AR, Jeyaseelan S, et al. Ethanol exposure impairs LPS-induced pulmonary LIX expression: alveolar epithelial cell dysfunction as a consequence of acute intoxication. Alcohol Clin Exp Res. 2009;33:357-365.
86. Jaques PA, Kim CS. Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women. Inhal Toxicol. 2000;12:715-731.
87. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2: 563-572.
88. O'Driscoll CM, Griffn BT. Biopharmaceutical challenges associated with drugs with low aqueous solubility - the potential impact of lipid-based formulations. Adv Drug Deliv Rev. 2008;60:617-624.
89. Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res. 1999;16:751-757.
90. Jacobs C, Kayser O, Müller RH. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm. 2000;196:161-164.
91. Boyd M, Risovic V, Jull P, Choo E, Wasan KM. A stepwise surgical procedure to investigate the lymphatic transport of lipid-based oral drug formulations: cannulation of the mesenteric and thoracic lymph ducts within the rat. J Pharmacol Toxicol Methods. 2004;49:115-120.
92. Edwards GA, Porter CJ, Caliph SM, Khoo SM, Charman WN. Animal models for the study of intestinal lymphatic drug transport. Adv Drug Deliv Rev. 2001;50:45-60.
93. Onizuka M, Flatebø T, Nicolaysen G. Lymph fow pattern in the intact thoracic duct in sheep. J Physiol.1997;503(Pt 1):223-234.
94. Segrave AM, Mager DE, Charman SA, Edwards GA, Porter CJ. Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. J Pharmacol Exp Ther. 2004;309:1085-1092.
95. White DG, Story MJ, Barnwell SG. An experimental model for studying the effects of a novel lymphatic drug delivery system for propranolol. Int J Pharm. 1991;69:169-174.
96. Bocci V, Muscettola M, Grasso G, Magyar Z, Naldini A, Szabo G. The lymphatic route. 1. Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasma. Experientia. 1986;42:432-433.
97. Khoo SM, Edwards GA, Porter CJ, Charman WN. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J Pharm Sci. 2001;90: 1599-1607.
98. Khoo SM, Shackleford DM, Porter CJ, Edwards GA, Charman WN. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs. Pharm Res. 2003;20:1460-1465.
99. Lespine A, Chanoit G, Bousquet-Melou A, et al. Contribution of lymphatic transport to the systemic exposure of orally administered moxidectin in conscious lymph duct-cannulated dogs. Eur J Pharm Sci. 2006;27:37-43.
100. Kagan L, Gershkovich P, Mendelman A, Amsili S, Ezov N, Hoffman A. The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm. 2007;67: 759-765.
101. Dahan A, Hoffman A. Evaluation of a chylomicron fow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur J Pharm Sci. 2005;24:381-388.
102. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60:702-716.
103. Yáez JA, Wang S W, Knemeyer I W, Wirth MA, Alton KB. Intestinal lymphatic transport for drug delivery. Adv Drug Deliv Rev. 2011;63: 923-942.
104. O'Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci. 2002;15:405-415.
105. Seeballuck F, Ashford MB, O'Driscoll CM. The effects of Pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. Pharm Res. 2003;20:1085-1092.
106. Seeballuck F, Lawless E, Ashford MB, O'Driscoll CM. Stimulation of triglyceride-rich lipoprotein secretion by polysorbate 80: in vitro and in vivo correlation using Caco-2 cells and a cannulated rat intestinal lymphatic model. Pharm Res. 2004;21:2320-2326.
107. Karpf DM, Holm R, Garafalo C, Levy E, Jacobsen J, Müllertz A. Effect of different surfactants in biorelevant medium on the secretion of a lipophilic compound in lipoproteins using Caco-2 cell culture. J Pharm Sci. 2006;95:45-55.
108. Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci. 2005;26: 394-404.
109. Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release. 2008;129:1-10.
110. Holm R, Hoest J. Successful in silico predicting of intestinal lymphatic transfer. Int J Pharm. 2004;272:189-193.
111. Chen H, Langer R. Oral particulate delivery: status and future trends. Adv Drug Deliv Rev. 1998;34:339-350.
112. Simon L. Special section on oral particulate absorption. J Drug Target. 1995;3:51-51.
113. Porter CJ, Charman WN. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev. 2001;50:61-80.
114. Luo G, Yu X, Jin C, et al. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm. 2010;385:150-156.
115. Oussoren C, Zuidema J, Crommelin DJ, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Infuence of liposomal size, lipid compostion and lipid dose. Biochim Biophys Acta. 1997;1328:261-272.
116. Kaminskas LM, Porter CJ. Targeting the lymphatics using dendritic polymers (dendrimers). Adv Drug Deliv Rev. 2011;63:890-900.
117. Patel HM, Boodle KM, Vaughan-Jones R. Assessment of the potential uses of liposomes for lymphoscintigraphy and lymphatic drug delivery. Failure of 99m-technetium marker to represent intact liposomes in lymph nodes. Biochim Biophys Acta. 1984;801:76-86.
118. Rao DA, Forrest ML, Alani AW, Kwon GS, Robinson JR. Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. J Pharm Sci. 2010;99:2018-2031.
119. Takakura Y, Atsumi R, Hashida M, Sezaki H. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular administration. Int J Pharm. 1987;37: 145-154.
120. Takakura Y, Hashida M, Sezaki H. Anatomy and physiology of the lymphatics. In: Charman WN, Stella VJ, editors. Lymphatic Transport of Drugs. Boca Raton, FL: CRC Press Inc; 1992.
121. Porter CJ. Drug delivery to the lymphatic system. Crit Rev Ther Drug Carrier Syst. 1997;14:333-393.
122. Clogston JD, Patri AK. Zeta potential measurement. Methods Mol Biol. 2011;697:63-70.
123. Kaur CD, Nahar M, Jain NK. Lymphatic targeting of zidovudine using surface-engineered liposomes. J Drug Target. 2008;16:798-805.
124. Dahlbäck B, Hermansson M, Kjelleberg S, Norkrans B. The hydrophobicity of bacteria - an important factor in their initial adhesion at the air-water interface. Arch Microbiol. 1981;128:267-270.
125. Patel HM. Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit Rev Ther Drug Carrier Syst. 1992;9:39-90.
126. Charman WN, Stella VJ. Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm. 1986;34:175-178.
127. Sanjula B, Shah FM, Javed A, Alka A. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J Drug Target. 2009;17:249-256.